TY - JOUR
T1 - EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence [Figure presented]
AU - Nambiar, Arjun K.
AU - Bosch, Ruud
AU - Cruz, Francisco
AU - Lemack, Gary E.
AU - Thiruchelvam, Nikesh
AU - Tubaro, Andrea
AU - Bedretdinova, Dina A.
AU - Ambühl, David
AU - Farag, Fawzy
AU - Lombardo, Riccardo
AU - Schneider, Marc P.
AU - Burkhard, Fiona C.
N1 - Funding Information:
Financial disclosures: Arjun K. Nambiar certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Nambiar received company speaker honorarium from Pfizer, received fellowships and travel grants from Astellas, Glaxo-SmithKline, and Ffizer and participated in trials for Allergan; Bosch is a company consultant for Astellas, Eli-Lilly, and Ferring AG, has received company speaker honoraria from GSK, AstraZeneca, Allergan, and Ferring AG, has participated in trials for Astellas, has received grants and research support from Astellas and Elli-Lilly; Cruz is a company consultant for Allergan, Recordati, Astellas, Ipsen, and Boston Scientific, has received speaker honoraria from Allergan, Recordati, Astellas, Pfizer, and AMS and has participated in trials for Allergan, Pfizer, Astellas Jansen, and Recordati; Lemack is a company consultant for Medtronic, has received speaker honoraria from Astellas and Allergan, has participated in trials for Sophiris, participated in a company sponsored speaker's bureau for Astellas and Allergan, and holds Pfizer stock; Thiruchelvam is a company consultant for Astellas, GSK, GT Urological, and Coloplast, has received company speaker honorarium from Astellas and GSK, received followships and travel grants from Astellas and Medtronic, and participated in trials for Pharmalys and Axonics. Tubaro is a company consultant for Allergan, Astellas, Bayer, Boston Scientific, GSK, and Takeda, has received speaker honorarium from Allergan, Astellas, and Pfizer, received grants and research support from AMS and Astellas, and participated in trials for AMS, Bayer, GSL, Pierre Fabre, and Takeda.
Publisher Copyright:
© 2018 European Association of Urology
PY - 2018/4
Y1 - 2018/4
N2 - Context: The European Association of Urology guidelines on urinary incontinence (UI) have been updated in cyclical fashion with successive major chapters being revised each year. The sections on assessment, diagnosis, and nonsurgical treatment have been updated as of mid-2016. Objective: We present a condensed version of the full guideline on assessment and nonsurgical management of UI, with the aim of improving accessibility and increasing their dissemination. Evidence acquisition: Our literature search was updated from the previous cut-off of July 2010 up to April 2016. Evidence synthesis was carried out by a pragmatic review of current systematic reviews and any newer subsequent high-quality studies, based on Population, Interevention, Comparator, and Outcome questions. Appraisal was conducted by an international panel of experts, working on a strictly nonprofit and voluntary basis, to develop concise evidence statements and action-based recommendations using modified Oxford and GRADE criteria. Evidence synthesis: The guidelines include algorithms that summarise the suggested pathway for standard, uncomplicated patients with UI and are more useable in daily practice. The full version of the guideline is available at http://uroweb.org/guideline/urinary-incontinence/. Conclusions: These updated guidelines provide an evidence-based summary of the assessment and nonsurgical management of UI, together with a clear clinical algorithm and action-based recommendations. Although these guidelines are applicable to a standard patient, it must be remembered that therapy should always be tailored to individual patients’ needs and circumstances. Patient summary: Urinary incontinence is a very common condition which negatively impacts patient's quality of life. Several types of incontinence exist and since the treatments will vary, it is important that the diagnostic evaluation establishes which type is present. The diagnosis should also identify patients who need rapid referral to an appropriate specialist. These guidelines aim to provide sensible and practical evidence-based guidance on the clinical problem of urinary incontinence. Urinary incontinence is a common and distressing symptom with a substantial effect on quality of life. The European Urology Association Guidelines Panel on Urinary Incontinence have used the best available evidence to provide pragmatic guidance to clinicians for initial assessment, and selection of the most appropriate conservative management options for patients seeking help for urinary incontinence.
AB - Context: The European Association of Urology guidelines on urinary incontinence (UI) have been updated in cyclical fashion with successive major chapters being revised each year. The sections on assessment, diagnosis, and nonsurgical treatment have been updated as of mid-2016. Objective: We present a condensed version of the full guideline on assessment and nonsurgical management of UI, with the aim of improving accessibility and increasing their dissemination. Evidence acquisition: Our literature search was updated from the previous cut-off of July 2010 up to April 2016. Evidence synthesis was carried out by a pragmatic review of current systematic reviews and any newer subsequent high-quality studies, based on Population, Interevention, Comparator, and Outcome questions. Appraisal was conducted by an international panel of experts, working on a strictly nonprofit and voluntary basis, to develop concise evidence statements and action-based recommendations using modified Oxford and GRADE criteria. Evidence synthesis: The guidelines include algorithms that summarise the suggested pathway for standard, uncomplicated patients with UI and are more useable in daily practice. The full version of the guideline is available at http://uroweb.org/guideline/urinary-incontinence/. Conclusions: These updated guidelines provide an evidence-based summary of the assessment and nonsurgical management of UI, together with a clear clinical algorithm and action-based recommendations. Although these guidelines are applicable to a standard patient, it must be remembered that therapy should always be tailored to individual patients’ needs and circumstances. Patient summary: Urinary incontinence is a very common condition which negatively impacts patient's quality of life. Several types of incontinence exist and since the treatments will vary, it is important that the diagnostic evaluation establishes which type is present. The diagnosis should also identify patients who need rapid referral to an appropriate specialist. These guidelines aim to provide sensible and practical evidence-based guidance on the clinical problem of urinary incontinence. Urinary incontinence is a common and distressing symptom with a substantial effect on quality of life. The European Urology Association Guidelines Panel on Urinary Incontinence have used the best available evidence to provide pragmatic guidance to clinicians for initial assessment, and selection of the most appropriate conservative management options for patients seeking help for urinary incontinence.
KW - Adults
KW - Diagnosis
KW - EAU guidelines
KW - Nonsurgical treatment
KW - Practice-based guidelines
KW - Urinary incontinence
UR - http://www.scopus.com/inward/record.url?scp=85041578890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041578890&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2017.12.031
DO - 10.1016/j.eururo.2017.12.031
M3 - Article
C2 - 29398262
AN - SCOPUS:85041578890
SN - 0302-2838
VL - 73
SP - 596
EP - 609
JO - European Urology
JF - European Urology
IS - 4
ER -